Skip to main content
OpenTrials
Completed

NCT Number: NCT01404364

Use of Intravitreal Triamcinolone and Retrobulbar Chlorpromazine as Alternatives to the Management of Painful Blind Eye

The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of ocular pain in blind eyes.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Blind Painful Eye Control of Pain Through Drug Injection Eye Diseases Glaucoma Ocular Hypertension Refractory Glaucoma

Age range

15 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Governador Celso Ramos

Florianópolis, Santa Catarina, 88015270, Brazil

About this study

The management of chronic eye pain is a constant challenge to ophthalmology. Treatment varies with the intensity of pain, and topical eye drops and contact lens therapy are effective in many patients. In refractory cases, and without vision, surgical removal of the eye through enucleation is considered classical therapy. As less invasive alternatives we have cyclodestruction and neurolytic drug injection in order to promote analgesia for a prolonged period.

The purpose of this study is to evaluate the efficacy of intravitreal triamcinolone and retrobulbar chlorpromazine as alternatives in the management of This is a prospective study of patients with blind painful eyes not responsive to topical treatment and with no indication for evisceration seen at the Department of Ophthalmology, Hospital Governador Celso Ramos (HGCR) in 2010.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • patients treated in the period at HGCR who wanted to be part of the protocol by signing the consent form

Exclusion criteria

  • patients whose follow-up period was less than three months

Treatment and study plan

Triamcinolone

Drug

0,3mL intravitreal injection of Triamcinolone, single dose

Chlorpromazine

Drug

2,5mL Chlorpromazine retrobulbar injection, single dose

Other names: Amplictil

Primary outcomes

  1. Changes in Pain intensity

    Time frame: 0, 1 month, 3 months, 6 months after procedure

    Pain was measured asking the patient to graduate it in a scale from 0 to 10, 0 being no pain, 10 being the worst pain patient has experienced in life

Secondary outcomes

  1. Changes in Use of eyedrops before and after drug injection

    Time frame: 0, 1 month, 3 months, 6 months

    Patient use of eyedrops before and after the procedure (yes or no)

  2. Changes in Intraocular pressure (IOP)

    Time frame: 0, 1 months, 3 months, 6 months

    IOP was measured at all times of patient evaluation

Sponsors and collaborators

Lead sponsor

Hospital Governador Celso Ramos

Other

Registry information

Important dates

Study start
2010
Primary completion
2010
Study completion
2010
First posted
Jul 28, 2011
Registry last updated
Jul 28, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.